Plain-English translation of NCT06788002 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a combination approach for people with nasopharyngeal cancer (a cancer in the back of the nose) that has spread to the liver. The combination includes low-dose radiation directed at the liver tumors, chemotherapy drugs called gemcitabine and cisplatin, and an immunotherapy medication called penpulimab. Researchers believe that combining these three treatments together may help fight the cancer more effectively than any single treatment alone.
Nasopharyngeal cancer that has spread to the liver is difficult to treat, and people need better treatment options. This trial is exploring whether adding immunotherapy to standard chemotherapy and radiation can improve outcomes for patients in this situation.
You likely qualify if…
You likely don't qualify if…
As a participant, you would receive the combination of low-dose radiation treatments directed at your liver metastases, along with chemotherapy infusions and the immunotherapy medication penpulimab. The exact schedule of visits and treatment duration will be determined by your study team, but you should expect regular clinic visits for treatment administration and monitoring with blood tests and scans to see how well the treatment is working. Your doctors will watch carefully for any side effects and adjust your care as needed.
AI-generated summary from trial data · Jul 17, 2026 · Not medical advice
China